Commercially focussed Chartered & European Patent Attorneys providing intellectual property (IP) services to innovative companies. Our experienced IP professionals deliver exceptional service and tangible results.
Secerna is a firm of commercially focussed Chartered & European Patent Attorneys. The team operates globally, representing and protecting the interests of multi-national corporations, FTSE and NYSE listed companies, universities, spin-out companies, small businesses and innovators worldwide.
We help our clients create and extract the maximum value from their intellectual property while minimizing costs, advising on the best IP strategies to meet their commercial goals. Our services include:
We represent our clients directly at the UK Intellectual Property Office, European Patent Office, and World International Property Organization in all aspects of intellectual property matters.
We build long-term business relationships with our clients, based on exceptional trust, teamwork and value for money.
We work hand in hand with you to find the best strategies to meet your business goals.
Our team combines considerable technical know-how and sector expertise with extensive commercial acumen.
Is your Intellectual Property a hidden asset or a vulnerable liability? Discover how to turn your ideas into a competitive advantage at our Intellectual Property (IP) Breakfast for Business Growth. Join us on Wednesday, May 28th, at York St John University in York for light bites, refreshments and to learn more about how IP is integral to your business growth.
Read moreThis series continues to explore the fascinating world of pharmaceuticals. Next up is U is for UPTRAVI. UPTRAVI® (from Johnson & Johnson) is used to treat pulmonary arterial hypertension (PAH) in adults.
Read moreThis series continues to explore the fascinating world of pharmaceuticals. Next up is T is for TECFIDERA. TECFIDERA (from Biogen) is a disease modifying therapy used for treating people with relapsing-remitting Multiple Sclerosis (MS).
Read moreThe European Patent Office (EPO) has released updated guidelines, effective April 1, 2025, clarifying the patentability of artificial intelligence (AI) and machine learning (ML) inventions. While the core principles remain consistent, the new guidelines emphasize that AI/ML inventions are considered technical and patentable if they are implemented by a computer and contribute to a technical solution.
Read moreBrexit brought changes, and if you're one of the many who now hold a 'Comparable UK Trade Mark' derived from an EU registration, you need to be aware of a crucial upcoming shift. From 2026, maintaining and enforcing these valuable UK rights hinges on actual use within the UK. Forget relying solely on past EU activity – the clock is ticking to ensure your brand is actively present in the UK market.
Read moreThis series continues to explore the fascinating world of pharmaceuticals. Next up is R is for REXULTI® (from Otsuka Pharmaceutical), also sold under the brand name RXULTI®, It is an antipsychotic medicine used to treat schizophrenia in adults. It is also used as an adjunctive therapy for the treatment of major depressive disorder.
Read more
